News - MedTech & Diagnostics
ADNeT study to assess impact of Roche Alzheimer’s test in primary care

The Australian Dementia Network (ADNeT) is leading a new study to evaluate whether Roche Diagnostics’ Elecsys pTau217 blood-based biomarker for Alzheimer’s disease can strengthen diagnostic confidence and inform clinical management in primary care.
The research comes amid a growing need for more accurate and accessible approaches to dementia diagnosis. Dementia is Australia’s leading cause of death, costing the nation more than $18 billion annually. More than 430,000 Australians are living with dementia, with Alzheimer’s disease accounting for approximately 70% of cases.
While advances in biomarker testing offer new opportunities to improve diagnostic pathways, access remains a challenge. Roche Diagnostics’ Elecsys pTau217 and pTau181 plasma assays, alongside Lilly’s Kisunla (donanemab), have received Therapeutic Goods Administration (TGA) approval for Alzheimer’s disease. However, neither is reimbursed for routine clinical access.
Among the emerging blood-based diagnostic tools, phosphorylated tau (p-tau)217 testing is preferred over p-tau181 because it produces fewer false-positive and false-negative results. The p-tau217 assay can help clinicians both rule in and rule out amyloid pathology, while p-tau181 is approved only as a rule-out test. Roche’s pTau217 has demonstrated 92% accuracy in detecting Alzheimer’s disease, compared with the current accuracy of 70% achieved even when diagnosis is undertaken by a specialist.
As these technologies evolve, understanding their practical value in general practice is essential. The extent to which blood-based biomarkers influence GPs’ diagnostic confidence, clinical decision-making and subsequent patient management remains a key question.
To investigate these issues, ADNeT is implementing the Blood-Based Biomarkers for Alzheimer’s Disease in Primary Care research project across Melbourne, Adelaide and Newcastle, led by ADNeT Director Professor Chris Rowe.
The project will examine GPs’ understanding of, and attitudes towards, diagnosing dementia and mild cognitive impairment (MCI) in general practice. It will also explore clinicians’ perspectives on using blood-based biomarkers to improve the diagnosis and management of early-stage Alzheimer’s disease and MCI.
The findings are expected to clarify the potential role of blood-based biomarkers in primary care and inform understanding of how these tests may support earlier diagnosis and clinical management.
In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.
The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.
News - MedTech & Diagnostics
Roche unlocks new horizons for genomic research in Asia Pacific
Roche is advancing its next-generation sequencing (NGS) ambitions in Asia Pacific following the global launch of AXELIOS 1 in June […]
MoreNews - Pharmaceuticals
‘Unexpected and surprising’: Novartis Lp(a) setback raises tough questions for Amgen and Lilly
The failure of Novartis’ lipoprotein(a) [Lp(a)] therapy to translate substantial biomarker reductions into meaningful cardiovascular benefits has been met with […]
MoreNews - MedTech & Diagnostics
More public hospitals turn to same-day hip and knee surgery, but key blind spots persist
Same-day hip and knee replacements to ease surgical waiting lists are being trialled at The Royal Adelaide Hospital (RAH), but […]
MoreNews - Pharmaceuticals
TGA approves oral Wegovy, prompting questions over efficacy and clinical positioning
The Therapeutic Goods Administration (TGA) approval of Novo Nordisk’s oral GLP-1 receptor agonist Wegovy (semaglutide) is introducing a new dimension to […]
More